According to Sania, its human-centric approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, with tuneable conditionally-activated ion channels.
This permits breakthrough efficacy by correcting dysfunctional neural excitation, thereby unlocking a broad range of diseases both within and beyond neurology.
The biotech’s foundational technology platforms were first developed at University College London by Sania’s co-founders.
The launch follows the closing of an oversubscribed Series Seed financing, proceeds of which have been applied to platform development, advancing a lead program in motor disorders, as well as initiating additional undisclosed programs which leverage platform capabilities.
Andy Murray, CEO and co-founder of Sania Therapeutics, said: "We formed Sania with a simple yet powerful vision: to be the first in developing medicines that treat disorders of neural circuits selectively. Today we are excited to demonstrate proof-of-principle data and unveil our platforms," said Andy Murray, CEO and co-founder of Sania Therapeutics."
"I'm very excited to be working with the team at Sania and believe their novel approach to neural modulation could lead to real benefits for patients," added Advisory Board member, Dr. Jane Hughes.
Sania will unveil its core patented technology platforms and proof-of-principle data at ASGCT on May 17 and 18. These platforms enable the precision delivery of proteins for neuromodulation to selected individual neural circuits.